Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) EBITDA (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of EBITDA readings, the most recent being -$4.1 million for Q1 2026.

  • On a quarterly basis, EBITDA fell 110.91% to -$4.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$9.5 million, a 39.26% increase, with the full-year FY2025 number at $32.7 million, up 138.36% from a year prior.
  • EBITDA hit -$4.1 million in Q1 2026 for Atara Biotherapeutics, down from -$3.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $38.0 million in Q1 2025 to a low of -$89.6 million in Q1 2022.
  • Median EBITDA over the past 5 years was -$21.9 million (2024), compared with a mean of -$33.0 million.
  • Biggest five-year swings in EBITDA: tumbled 499.12% in 2023 and later soared 220.25% in 2025.
  • Atara Biotherapeutics' EBITDA stood at -$73.7 million in 2022, then rose by 18.45% to -$60.1 million in 2023, then soared by 78.85% to -$12.7 million in 2024, then skyrocketed by 73.19% to -$3.4 million in 2025, then fell by 21.69% to -$4.1 million in 2026.
  • The last three reported values for EBITDA were -$4.1 million (Q1 2026), -$3.4 million (Q4 2025), and -$4.3 million (Q3 2025) per Business Quant data.